Thus, employing immunosuppressants to inhibit the expression of CTLA4 or FOXP3 may emerge as a potential treatment strategy for HER2-amplified subtypes of ICC. The gene discussed is CTLA4; the disease is intrahepatic cholangiocarcinoma.